ko	pathway	ratio_in_study	ratio_in_pop	p_value
ko01522	Endocrine resistance	7/51	124/7206	2.32860277863e-05
ko05205	Proteoglycans in cancer	9/51	271/7206	9.99997369144e-05
ko04668	TNF signaling pathway	6/51	120/7206	0.000183738824796
ko05212	Pancreatic cancer	5/51	83/7206	0.000278348847644
ko05200	Pathways in cancer	11/51	492/7206	0.000523873599669
ko05146	Amoebiasis	5/51	99/7206	0.000629759402845
ko01521	EGFR tyrosine kinase inhibitor resistance	5/51	106/7206	0.000859722410107
ko05224	Breast cancer	6/51	174/7206	0.00132977718989
ko04060	Cytokine-cytokine receptor interaction	6/51	191/7206	0.00214026211493
ko04933	AGE-RAGE signaling pathway in diabetic complications	5/51	135/7206	0.0025215991338
ko05210	Colorectal cancer	4/51	86/7206	0.00308367347131
ko05211	Renal cell carcinoma	4/51	96/7206	0.00458036582623
ko05100	Bacterial invasion of epithelial cells	4/51	99/7206	0.00511040206558
ko05410	Hypertrophic cardiomyopathy (HCM)	4/51	100/7206	0.00529586086906
ko04520	Adherens junction	4/51	103/7206	0.00587925663655
ko04068	FoxO signaling pathway	5/51	167/7206	0.00625555181138
ko04510	Focal adhesion	6/51	240/7206	0.00658458843213
ko05321	Inflammatory bowel disease (IBD)	3/51	56/7206	0.00711213201622
ko04012	ErbB signaling pathway	4/51	109/7206	0.00717186862292
ko05161	Hepatitis B	5/51	173/7206	0.00724517119113
ko05215	Prostate cancer	4/51	111/7206	0.00764135748611
ko04932	Non-alcoholic fatty liver disease (NAFLD)	5/51	182/7206	0.00892843154591
ko05213	Endometrial cancer	3/51	62/7206	0.00941988214453
ko04330	Notch signaling pathway	3/51	62/7206	0.00941988214453
ko04144	Endocytosis	7/51	342/7206	0.0097503997491
ko05221	Acute myeloid leukemia	3/51	63/7206	0.00984214154057
ko04810	Regulation of actin cytoskeleton	6/51	264/7206	0.0103175172979
ko04912	GnRH signaling pathway	4/51	122/7206	0.0105881089267
ko04750	Inflammatory mediator regulation of TRP channels	4/51	122/7206	0.0105881089267
ko04211	Longevity regulating pathway	4/51	123/7206	0.0108877154307
ko05223	Non-small cell lung cancer	3/51	66/7206	0.011174617607
ko04915	Estrogen signaling pathway	4/51	131/7206	0.0134838339864
ko04730	Long-term depression	3/51	78/7206	0.0175112345196
ko05412	Arrhythmogenic right ventricular cardiomyopathy (ARVC)	3/51	79/7206	0.0181131585596
ko04512	ECM-receptor interaction	3/51	79/7206	0.0181131585596
ko05214	Glioma	3/51	79/7206	0.0181131585596
ko05131	Shigellosis	3/51	82/7206	0.0199878406993
ko04320	Dorso-ventral axis formation	2/51	31/7206	0.0200356912763
ko05218	Melanoma	3/51	85/7206	0.0219661434419
ko05220	Chronic myeloid leukemia	3/51	85/7206	0.0219661434419
ko05160	Hepatitis C	4/51	153/7206	0.0225566834737
ko04071	Sphingolipid signaling pathway	4/51	162/7206	0.0271320637164
ko04672	Intestinal immune network for IgA production	2/51	37/7206	0.027935812519
ko04658	Th1 and Th2 cell differentiation	3/51	96/7206	0.0301079153488
ko05206	MicroRNAs in cancer	4/51	177/7206	0.0359214228376
ko05144	Malaria	2/51	45/7206	0.0400704660205
ko05414	Dilated cardiomyopathy	3/51	112/7206	0.0444177773917
ko05219	Bladder cancer	2/51	48/7206	0.045050830073
ko04015	Rap1 signaling pathway	5/51	278/7206	0.0456712870613
ko04024	cAMP signaling pathway	5/51	279/7206	0.0462618844945
ko04072	Phospholipase D signaling pathway	4/51	197/7206	0.0499477214332